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Abstract
Aortic Valve Disease, includes a range of disorder severity from mild leaflet thickening without
valve obstruction, "aortic sclerosis", to severe calcified aortic stenosis. It is a slowly progressive
active process of valve modification similar atherosclerosis for cardiovascular risk factors,
lipoprotein deposition, chronic inflammation, and calcification. Systemic signs of inflammation, as
wall and serum CRP, similar to those found in atherosclerosis, are present in patients with
degenerative aortic valve stenosis and may be expression of a common disease, useful in monitoring
of stenosis progression.
Aortic stenosis (AS) is at present time the most frequent
valvulopaty in developed countries, and as life expectancy
increases, the incidence and prevalence of AS will also rise
fundamentally at the expense of the degenerative form.
The scientific interest of this valvar disorder was parked
for many years, as the image tools necessary to quantify it
are at our disposal and we have a certain agreement of the
clinical moment for indicating the valve replacement.
Nevertheless, in the past years different studies have dem-
onstrated a common pathogenic mechanism between
degenerative AS and atherosclerosis [1-3]. This is consist-
ent with histopathological evidence that the lesions in AS
involve active cellular processes that have classical
"response to injury features", namely inflammatory infil-
trates containing macrophages, T cells, and smooth mus-
cle cells [4]. Therefore, investigators have needed only a
half turn of the head to transfer the early past experience
of blood markers of inflammation in the atherosclerosis
setting to the AS scenario.
C-reactive protein (CRP) is the marker of inflammation
most widely studied in patients with coronary artery dis-
ease and hence has become the marker of reference for
any other inflammatory-based disease [5]. On this basis,
CRP has emerged as a leading candidate for a better
understanding of AS pathogenesis, for predicting AS pro-
gression, and for driving therapies in AS.
CRP is increased in patients with AS
The first study showing increased CRP levels in patients
with degenerative AS was published by Galante et al, in
2001 [6]. They compared serum CRP levels of 68 consec-
utive patients with severe degenerative trileaflet AS and
absence of coronary atherosclerotic lesions admitted for
elective cardiac surgery with 92 healthy controls. CRP lev-
els were higher in patients with AS than in controls (0.85
± 1.42 vs. 0.39 ± 0.50; p = 0.0001). They also showed an
independent association of CRP with AS; the odds ratio
for the disease according to CRP levels were 2.62 (95%
confidence interval: 1.06 to 6.49). No association
between CRP and aortic jet velocity, aortic valve area, or
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degree of calcification was found, notwithstanding that all
patients had severe aortic stenosis and were waiting for
surgery.
Further studies have confirmed [1] and expanded these
observations. Serum CRP is also elevated in patients with
asymptomatic aortic stenosis [7,8], does not rise in
accordance with increasing severity of valvar disease [7,8],
and decreased from before to 6 months after aortic valve
replacement [9].
One of the principal characteristics of AS is the important
degree of valvar calcification that takes place along the dif-
ferent stages of the disease. Thus, investigating whether
CRP could be related to the mechanism of calcification
appears very atractive. The role of serum CRP in the tissue
calcification process has been investigated in a recently
elegant study by Warrier et al,. When aortic wall was
exposed to an excess amount of CRP in an in vitro simu-
lating model, the calcification rate of aortic wall increased
as the concentration of CRP. The results of this work could
revealed the role of CRP present in physiological fluid in
aortic valvar calcification [10]. Data providing contribu-
tion of serum CRP to valve calcification in the clinical set-
ting is available in patients with renal failure. Valvar
calcification in patients with renal failure is associated
with enhanced inflammation [11]. Furthermore, in
chronic hemodyalisis patients in steady clinical condi-
tions with no clinical evidence of either infectious or
inflammatory diseases, a high CaxPO4 is associated with
high CRP concentrations and hence associated with valvar
calcification [12,13]. However, preliminary transversal
evidence evaluating the association of CRP and calcifica-
tion in patients with AS and no renal failure is controver-
sial [6-8]; thus, the long-term predictive value of the
serum CRP level for the development of aortic calcifica-
tion should be addressed in future well design prospective
trials.
Recently, Skowasch et al, have observed localization of
CRP in valve tissue of degenerative AS and degenerative
aortic valve bioprostheses [14]. Furthermore, serum CRP
showed a significant correlation with the valvar CRP
expression (r = 0.54; P < 0.001). Consequently, we must
integrate our previous understanding of the physiological
role of CRP in inflamed tissues, thereby promoting local
anti-inflammatory and proinflammatory effects [15]. It
has been suggested that the effects of CRP on human aor-
tic endothelial cells are similar to those seen in atheroscle-
rotic models i.e. inducing the amplification of local
inflammation and cellular damage [16,17].
CRP and progression of AS
We have assessed whether serum CRP levels could predict
rapid AS progression. We measured serum high sensitivity
CRP in 43 asymptomatic subjects with AS at baseline and
six months later. Plasma CRP concentration was signifi-
cantly higher in patients with rapid AS progression (5.1
[2.3 to 11.3] mg/L) compared to patients with slow AS
progression (2.1 [1.0 to 3.1] mg/L, p = 0.007). The rate of
progression, was higher in patients who had a cutpoint
level of CRP >3 mg/L than those who had levels ≤ 3 mg/L
(66.7% vs 33.3%, p = 0.012 for aortic jet velocity and
62.5% vs 37.5%, p = 0.063 for aortic valve area, figure 1
and 2). Little is known of the mechanisms responsible for
progression of AS albeit mechanical, clinical, and meta-
bolic variables have been suggested to contribute to rapid
progression of AS [18,19]. Our data suggest that elevated
CRP levels may be a marker of AS progression and could
have important clinical implications as interventions that
reduce CRP levels may be beneficial in the prevention of
AS and perhaps also in reducing AS progression.
Finally, baseline CRP concentration, was similar in
patients who developed symptoms compared to those
asymptomatic during follow-up. Data in patients with
aortic sclerosis suggest a positive association between the
risk of adverse cardiovascular events and the presence of
coronary artery disease (hazard ratio [HR] 3.23, p =
0.003) and enhanced inflammation (HR 2.2, p = 0.001),
and not as a result of the effects of valvar heart disease per
se [20].
Targeting CRP for the therapy of AS
The presence of higher serum CRP levels and the tissue
location of CRP in patients with AS, have raised the
important question of whether medical therapies with
Rate of CRP > 3 mg/L in patients with slow and rapid aortic  stenosis progression according to the assesment of aortic jet  velocity (Cw) Figure 1
Rate of CRP > 3 mg/L in patients with slow and rapid aortic 
stenosis progression according to the assesment of aortic jet 
velocity (Cw). Slow and rapid progressors were considered 
those patients with an increase in aortic jet velocity < or ≥ 
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agents such as statins and ACE inhibitors, which have
already been shown to delay the progression of athero-
sclerosis may also affect the progression of AS.
Preclinical studies, have shown that experimental hyperc-
holesterolemia provide evidence of a proliferative athero-
sclerosis-like process in the aortic valve that is inhibited by
statins [21-23]; ie, atorvastatin inhibited calcification in
the aortic valve by increasing eNOS protein and serum
nitrite concentrations [22], and decreasing Lrp5 (low-den-
sity receptor-related protein) receptors involve in cellular
proliferation and osteoblastogenesis via the beta-catenin
signaling pathway [23].
Although recent retrospective clinical studies suggest that
statins also may slow the hemodynamic progression of AS
[24-28], the results of the SALTIRE study have been dis-
couraging for all of us who believe that AS is an active dis-
ease process akin to atherosclerosis with lipoprotein
deposition, chronic inflammation, and active leaflet calci-
fication [29]. Therefore, It is important to analyze the neu-
tral effect of high doses of atorvastatin in such an
attractive hypothesis. First, the SALTIRE study differs not
only because of its prospective design but also because the
indications for therapy were different. In the retrospective
trials, statin therapy was indicated for the treatment of
hyperlipidemia, whereas in the prospective trial, patients
in whom statins were indicated for the treatment of hyper-
lipidemia were excluded. Second, statin doses in the retro-
spective studies were lower. Finally, although the
observation periods in the various studies were similar,
patients in the retrospective studies were already receiving
therapy at the time of inclusion in the study [30]. Aside
from the already commented differences with retrospec-
tive studies, high proportion of patients were on drugs
with anti-inflammatory effects (apirin, betablockers or
angiotensin converting enzyme inhibitors) that could
have mitigated the pleiotropic effect of statins. For exam-
ple, in the retrospective trials that found a lower rate of
progression among patients treated with statins, the per-
centage of patients on aspirin was always important and
significantly higher in the group with positive results
[25,27,28]. Importantly, in the SALTIRE study, half of the
patients in each group were on aspirin, a prevalence that
would have a bearing on the results of the study. In addi-
tion, markers of inflammation would have been useful as
a means to predict or monitor the individual's response to
atorvastatin. If the authors were not just looking for a
reduction cholesterol effects it is surprising that they have
not yet provided any information about inflammatory
effects. As the main finding, Skowasch et al, [14] in their
recent study showed that both valvar CRP expression and
serum CRP levels were found to be lower in patients on
statins.
Moving forward, we must learn more about the patho-
genic mechanisms of AS. We must integrate the athero-
sclerotic background of inflammatory biomarkers in our
future research, and finally we must focus on the develop-
ment of prospective, randomised trials using CRP to mon-
itor the individual's response to treatments.
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